- Home
- PHAR vs BYRN Comparison
PHAR vs BYRN Comparison
Compare PHAR & BYRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- BYRN
- Stock Information
- Founded
- PHAR 1988
- BYRN 2005
- Country
- PHAR Netherlands
- BYRN United States
- Employees
- PHAR N/A
- BYRN N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- BYRN Industrial Machinery/Components
- Sector
- PHAR Health Care
- BYRN Miscellaneous
- Exchange
- PHAR Nasdaq
- BYRN Nasdaq
- Market Cap
- PHAR 707.9M
- BYRN 670.5M
- IPO Year
- PHAR N/A
- BYRN N/A
- Fundamental
- Price
- PHAR $10.96
- BYRN $21.32
- Analyst Decision
- PHAR Strong Buy
- BYRN Strong Buy
- Analyst Count
- PHAR 3
- BYRN 2
- Target Price
- PHAR $30.00
- BYRN $41.50
- AVG Volume (30 Days)
- PHAR 5.3K
- BYRN 911.0K
- Earning Date
- PHAR 07-31-2025
- BYRN 07-10-2025
- Dividend Yield
- PHAR N/A
- BYRN N/A
- EPS Growth
- PHAR N/A
- BYRN N/A
- EPS
- PHAR N/A
- BYRN 0.62
- Revenue
- PHAR $339,836,000.00
- BYRN $103,528,000.00
- Revenue This Year
- PHAR $12.88
- BYRN $38.01
- Revenue Next Year
- PHAR $8.54
- BYRN $21.31
- P/E Ratio
- PHAR N/A
- BYRN $34.24
- Revenue Growth
- PHAR 22.44
- BYRN 73.56
- 52 Week Low
- PHAR $6.73
- BYRN $7.79
- 52 Week High
- PHAR $12.61
- BYRN $34.78
- Technical
- Relative Strength Index (RSI)
- PHAR 58.06
- BYRN 33.97
- Support Level
- PHAR $9.54
- BYRN $20.22
- Resistance Level
- PHAR $10.46
- BYRN $24.15
- Average True Range (ATR)
- PHAR 0.37
- BYRN 1.22
- MACD
- PHAR 0.10
- BYRN -0.10
- Stochastic Oscillator
- PHAR 81.20
- BYRN 27.03
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.